Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma

被引:3
作者
Zhou, G-K [1 ]
Zhang, G-Y [2 ]
Yuan, Z-N [1 ]
Pei, R. [1 ]
Liu, D-M [1 ]
机构
[1] Harbin Med Univ Canc Hosp, Dept Head & Neck Surg, Harbin, Heilongjiang, Peoples R China
[2] First Hosp Harbin, Dept Pharm, Harbin, Heilongjiang, Peoples R China
关键词
Has_circ_0008274; Papillary thyroid carcinoma; Proliferation; Invasion; AMPK/mTOR signaling pathway; CIRCULAR RNAS; CANCER; BIOGENESIS; APOPTOSIS; MTOR;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Circular RNAs (circRNAs) have been known as important regulators in tumorigenesis. Whether circRNAs are involved in papillary thyroid carcinoma (PTC) requires to be determined. In the present study, we aimed to investigate the expression and function of has_circ_0008274 in PTC. PATIENTS AND METHODS: Tissue expression of has circ 0008274 was evaluated in Gene Expression Omnibus datasets (GSE93522). Real-time PCR assays were used to detect the expression of has_circ_0008274 in human PTC tissues and cell lines. The correlation of has_circ_0008274 expression with clinicopathological factors was statistically analyzed. The MTT assay, colony formation assay, transwell assays were performed to analyze and compare cell viability and invasion. Western blot analysis was used to quantify the expression of AMPK/mTOR signaling pathway proteins. RESULTS: We found that has_circ_0008274 was significantly upregulated in PTC tissues, and the level of has_circ_0008274 was negatively associated with TNM stage and lymph node metastasis. Loss-of-function assay indicated that knockdown of has_circ_0008274 suppressed PTC cells proliferation and invasion in vitro. Mechanistically, has_circ_0008274 could inhibit the activation of AMPK/mTOR signaling pathway, which was demonstrated by measuring the expression levels of p-AMPK and p-mTOR. CONCLUSIONS: These results demonstrate that increased has_circ_0008274 expression modulates has_circ_0008274 to enhance PTC cells proliferation and invasion. Has_circ_0008274/ AMPK/mTOR axis may be a novel therapeutic candidate target in PTC treatment.
引用
收藏
页码:8772 / 8780
页数:9
相关论文
共 35 条
  • [11] Liu TR, 2016, EUR REV MED PHARMACO, V20, P3582
  • [12] Papillary Thyroid Carcinoma Variants
    Lloyd R.V.
    Buehler D.
    Khanafshar E.
    [J]. Head and Neck Pathology, 2011, 5 (1) : 51 - 56
  • [13] Noncoding RNAs, cytokines, and inflammation-related diseases
    Marques-Rocha, Jose Luiz
    Samblas, Mirian
    Milagro, Fermin I.
    Bressan, Josefina
    Alfredo Martinez, J.
    Marti, Amelia
    [J]. FASEB JOURNAL, 2015, 29 (09) : 3595 - 3611
  • [14] Metformin: Its emerging role in oncology
    Micic, Dragan
    Cvijovic, Goran
    Trajkovic, Vladimir
    Duntas, Leonidas H.
    Polovina, Snezana
    [J]. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2011, 10 (01): : 5 - 15
  • [15] Lymph Node Dissection in Papillary Thyroid Carcinoma
    Moo, Tracy-Ann S.
    Fahey, Thomas J., III
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2011, 41 (02) : 84 - 88
  • [16] Osaki M, 2015, THER DELIV, V6, P323, DOI [10.4155/TDE.14.122, 10.4155/tde.14.122]
  • [17] The Treatment of Well-Differentiated Thyroid Carcinoma
    Paschke, Ralf
    Lincke, Thomas
    Mueller, Stefan P.
    Kreissl, Michael C.
    Dralle, Henning
    Fassnacht, Martin
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (26): : 452 - 458
  • [18] Early history of circular RNAs, children of splicing
    Pasman, Zvi
    Garcia-Blanco, Mariano A.
    [J]. RNA BIOLOGY, 2017, 14 (08) : 975 - 977
  • [19] Microarray profiling of circular RNAs in human papillary thyroid carcinoma
    Peng, Nianchun
    Shi, Lixin
    Zhang, Qiao
    Hu, Ying
    Wang, Nanpeng
    Ye, Hui
    [J]. PLOS ONE, 2017, 12 (03):
  • [20] Diffuse sclerosing variant of papillary thyroid carcinoma-an update of its clinicopathological features and molecular biology
    Pillai, Suja
    Gopalan, Vinod
    Smith, Robert A.
    Lam, Alfred K. -Y.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (01) : 64 - 73